|
| 22 | Commentary: Where and How Could Biomarkers Be Used in 2016 M. J. Finley Austin, Lee Babiss [Full Text] [PDF] |
|
| 1 | Current Industrial Practices of Assessing Permeability and P-Glycoprotein Interaction Praveen V. Balimane, Yong-Hae Han, Saeho Chong [Abstract] [Full Text] [PDF] |
| 3 | Genetic Factors in the Predisposition to Drug-induced Hypersensitivity Reactions Munir Pirmohamed [Abstract] [Full Text] [PDF] |
| 4 | Recent Progress in the Computational Prediction of Aqueous Solubility and Absorption Stephen R. Johnson, Weifan Zheng [Abstract] [Full Text] [PDF] |
| 5 | The Chinchilla Microdialysis Model for the Study of Antibiotic Distribution to Middle Ear Fluid Belinda W. Y. Cheung, Wei Liu, Ping Ji, Linda L. Cartier, Zhihong Li, Nael Mostafa, Ronald J. Sawchuk [Abstract] [Full Text] [PDF] |
| 6 | Mechanisms of Drug-Induced Liver Injury Michael P. Holt, Cynthia Ju [Abstract] [Full Text] [PDF] |
| 7 | Role of Bioactivation in Drug-Induced Hypersensitivity Reactions Joseph P. Sanderson, Dean J. Naisbitt, B. Kevin Park [Abstract] [Full Text] [PDF] |
| 8 | Current Status of Immunologic Approaches to Treating Tobacco Dependence: Vaccines and Nicotine-specific Antibodies Mark G. LeSage, Daniel E. Keyler, Paul R. Pentel [Abstract] [Full Text] [PDF] |
| 9 | CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier Ken A. Witt, Thomas P. Davis [Abstract] [Full Text] [PDF] |
| 10 | Safety Biomarkers and the Clinical Development of Oncology Therapeutics: Considerations for Cardiovascular Safety and Risk Management Howard Fingert, Mary Varterasian [Abstract] [Full Text] [PDF] |
| 11 | Detergent-Resistant Membrane Microdomains in the Disposition of the Lipid Signaling Molecule Anandamide Matthew J. McFarland, Ekaterina A. Terebova, Eric L. Barker [Abstract] [Full Text] [PDF] |
| 12 | Cytochrome P450s and Other Enzymes in Drug Metabolism and Toxicity F. Peter Guengerich [Abstract] [Full Text] [PDF] |
| 13 | Activation of G-proteins in Brain by Endogenous and Exogenous Cannabinoids Steven R. Childers [Abstract] [Full Text] [PDF] |
| 14 | Opioid Ligands With Mixed µ/d Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics Subramaniam Ananthan [Abstract] [Full Text] [PDF] |
| 15 | Molecular Recognition of Opioid Receptor Ligands Brian E. Kane, Bengt Svensson, David M. Ferguson [Abstract] [Full Text] [PDF] |
| 16 | Receptors of Mammalian Trace Amines Anita H. Lewin [Abstract] [Full Text] [PDF] |
| 17 | Blood Pressure as an Example of a Biomarker That Functions as a Surrogate Mehul Desai, Norman Stockbridge, Robert Temple [Abstract] [Full Text] [PDF] |
| 18 | Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development Achla Gupta, Fabien M. Décaillot, Lakshmi A. Devi [Abstract] [Full Text] [PDF] |
| 19 | Noncovalent Interactions of Drugs With Immune Receptors May Mediate Drug-induced Hypersensitivity Reactions Basil O. Gerber, Werner J. Pichler [Abstract] [Full Text] [PDF] |
| 21 | Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse Joni L. Rutter [Abstract] [Full Text] [PDF] |
| 23 | Mutant Glycosyltransferases Assist in the Development of a Targeted Drug Delivery System and Contrast Agents for MRI Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman [Abstract] [Full Text] [PDF] |
| 24 | Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse F. Ivy Carroll, James L. Howard, Leonard L. Howell, Barbara S. Fox, Michael J. Kuhar [Abstract] [Full Text] [PDF] |
| 25 | Selectivity and Potency of Cyclin-dependent Kinase Inhibitors Jayalakshmi Sridhar, Nagaraju Akula, Nagarajan Pattabiraman [Abstract] [Full Text] [PDF] |
|
| 2 | The Pharmacokinetics of Escitalopram in Patients With Hepatic Impairment Johan Areberg, Jacob Strøyer Christophersen, Mette Nøhr Poulsen, Frank Larsen, Karl-Heinz Molz [Abstract] [Full Text] [PDF] |
| 20 | Effect of N-1 and N-2 Residues on Peptide Deamidation Rate in Solution and Solid State Bei Li, Richard L. Schowen, Elizabeth M. Topp, Ronald T. Borchardt [Abstract] [Full Text] [PDF] |